Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli Muchtar

Showing results (1-10 of 263) with videos related to

Pageof 27
Sort By:
Therapeutic Advances in Hematology|August 6, 2016
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentHila Magen, Eli Muchtar
Blood|November 20, 2025
Isatuximab: surface strike, deep response in AL amyloidosisEli Muchtar, Angela Dispenzieri
Leukemia & Lymphoma|April 15, 2016
Lenalidomide - the new melphalan?Eli Muchtar, Morie Gertz
Expert Opinion on Orphan Drugs|September 27, 2021
Clinical trials evaluating potential therapies for light chain (AL) amyloidosisEli Muchtar, Morie A Gertz
JACC. Cardiooncology|October 23, 2025
The FLC Ratio Reframed: Averting Unnecessary Heart Biopsies in Wild-Type ATTR AmyloidosisEli Muchtar, Mathew S Maurer
Leukemia & Lymphoma|February 28, 2019
The colorful landscape of multiple myelomaEli Muchtar, Morie A Gertz
Current Hematologic Malignancy Reports|May 13, 2020
Updates in the Diagnosis and Management of AL AmyloidosisJoselle Cook, Eli Muchtar, Rahma Warsame
The Canadian Journal of Cardiology|March 9, 2020
The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain AmyloidosisEli Muchtar, Grace Lin, Martha Grogan
Oncotarget|November 16, 2017
Importance of FISH genetics in light chain amyloidosisMorie A Gertz, Angela Dispenzieri, Eli Muchtar
European Journal of Haematology|February 20, 2016
A practical review on carfilzomib in multiple myelomaEli Muchtar, Morie A Gertz, Hila Magen
Pageof 27

Showing results (1-10 of 263) with videos related to

Sort By:
Pageof 27
Therapeutic Advances in Hematology|August 6, 2016
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentHila Magen, Eli Muchtar
Blood|November 20, 2025
Isatuximab: surface strike, deep response in AL amyloidosisEli Muchtar, Angela Dispenzieri
Leukemia & Lymphoma|April 15, 2016
Lenalidomide - the new melphalan?Eli Muchtar, Morie Gertz
Expert Opinion on Orphan Drugs|September 27, 2021
Clinical trials evaluating potential therapies for light chain (AL) amyloidosisEli Muchtar, Morie A Gertz
JACC. Cardiooncology|October 23, 2025
The FLC Ratio Reframed: Averting Unnecessary Heart Biopsies in Wild-Type ATTR AmyloidosisEli Muchtar, Mathew S Maurer
Leukemia & Lymphoma|February 28, 2019
The colorful landscape of multiple myelomaEli Muchtar, Morie A Gertz
Current Hematologic Malignancy Reports|May 13, 2020
Updates in the Diagnosis and Management of AL AmyloidosisJoselle Cook, Eli Muchtar, Rahma Warsame
The Canadian Journal of Cardiology|March 9, 2020
The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain AmyloidosisEli Muchtar, Grace Lin, Martha Grogan
Oncotarget|November 16, 2017
Importance of FISH genetics in light chain amyloidosisMorie A Gertz, Angela Dispenzieri, Eli Muchtar
European Journal of Haematology|February 20, 2016
A practical review on carfilzomib in multiple myelomaEli Muchtar, Morie A Gertz, Hila Magen
Pageof 27